TScan Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TCRX and other ETFs, options, and stocks.About TCRX
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts.
CEOGavin MacBeath
CEOGavin MacBeath
Employees194
Employees194
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2018
Founded2018
Employees194
Employees194
TCRX Key Statistics
Market cap61.57M
Market cap61.57M
Price-Earnings ratio-0.96
Price-Earnings ratio-0.96
Dividend yield—
Dividend yield—
Average volume819.12K
Average volume819.12K
High today$1.15
High today$1.15
Low today$1.05
Low today$1.05
Open price$1.11
Open price$1.11
Volume978.25K
Volume978.25K
52 Week high$4.85
52 Week high$4.85
52 Week low$0.91
52 Week low$0.91
Stock Snapshot
TScan Therapeutics(TCRX) stock is priced at $1.09, giving the company a market capitalization of 61.57M. It carries a P/E multiple of -0.96.
On 2025-12-07, TScan Therapeutics(TCRX) stock traded between a low of $1.05 and a high of $1.15. Shares are currently priced at $1.09, which is +3.8% above the low and -5.2% below the high.
The TScan Therapeutics(TCRX)'s current trading volume is 978.25K, compared to an average daily volume of 819.12K.
During the past year, TScan Therapeutics(TCRX) stock moved between $0.91 at its lowest and $4.85 at its peak.
During the past year, TScan Therapeutics(TCRX) stock moved between $0.91 at its lowest and $4.85 at its peak.
Analyst ratings
71%
of 7 ratingsBuy
71.4%
Hold
28.6%
Sell
0%
People also own
Based on the portfolios of people who own TCRX. This list is generated using Robinhood data, and it’s not a recommendation.